{"title":"过敏原免疫疗法的临床终点：2022 年最新进展。","authors":"Roy Gerth van Wijk, Ludger Klimek, Oliver Pfaar","doi":"10.5414/ALX02334E","DOIUrl":null,"url":null,"abstract":"<p><p>110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.</p>","PeriodicalId":7485,"journal":{"name":"Allergologie Select","volume":"7 ","pages":"39-46"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012882/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical endpoints in allergen immunotherapy: State of the art 2022.\",\"authors\":\"Roy Gerth van Wijk, Ludger Klimek, Oliver Pfaar\",\"doi\":\"10.5414/ALX02334E\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.</p>\",\"PeriodicalId\":7485,\"journal\":{\"name\":\"Allergologie Select\",\"volume\":\"7 \",\"pages\":\"39-46\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012882/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologie Select\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5414/ALX02334E\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie Select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02334E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
诺恩的经典研究问世 110 年后，众多研究证实了过敏原免疫疗法的疗效。这些试验采用了多种临床终点。本综述概述了鼻炎和哮喘过敏原免疫疗法（AIT）随机临床试验的临床终点。此外，现实生活中的研究也采用了同类终点。一般来说，AIT 研究的特点是缺乏标准化和有效的结果测量。针对过敏性鼻结膜炎，已开发出监测患者的数字工具。这些工具对于获取 AIT 的真实世界证据尤为有用。最后，成本效益研究可以采用公认的结果测量方法。
Clinical endpoints in allergen immunotherapy: State of the art 2022.
110 years after the classical study by Noon, numerous studies have confirmed the efficacy of allergen immunotherapy. A variety of clinical endpoints have been used in these trials. This review gives an overview of clinical endpoints for randomized clinical trials on allergen immunotherapy (AIT) in rhinitis and asthma. In addition, real-life studies have been carried out with the same kind of endpoints. In general, AIT studies are characterized by a lack of standardized and validated outcome measures. For allergic rhinoconjunctivitis, digital tools have been developed to monitor patients. Such tools are particularly useful to obtain real-world evidence for AIT. Finally, well-accepted outcome measures are available for cost-effectiveness studies.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
